Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ascend Wellness Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $667.9 Mil.
Ascend Wellness Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascend Wellness Holdings EV-to-EBIT Related Terms
Ascend Wellness Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ascend Wellness Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascend Wellness Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ascend Wellness Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ascend Wellness Holdings's EV-to-EBIT falls into.
Ascend Wellness Holdings's current Enterprise Value is $649.7 Mil.
Ascend Wellness Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascend Wellness Holdings (AAWH) has a EV-to-EBIT of -40.75 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ascend Wellness Holdings and its competitors. According to the industry distribution chart, Ascend Wellness Holdings ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Ascend Wellness Holdings' EV-to-EBIT too high?
Ascend Wellness Holdings' current EV-to-EBIT is -40.75. Based on the distribution chart, Ascend Wellness Holdings ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ascend Wellness Holdings has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascend Wellness Holdings' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ascend Wellness Holdings ranks #999999 out of 690 companies for EV-to-EBIT. This places Ascend Wellness Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ascend Wellness Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascend Wellness Holdings's current EV-to-EBIT is -40.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascend Wellness Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ascend Wellness Holdings (AAWH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.40 — trading 45.2% below its estimated fair value. The current EV-to-EBIT is -40.75. Ascend Wellness Holdings' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ascend Wellness Holdings (AAWH), the current EV-to-EBIT is -40.75 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascend Wellness Holdings (AAWH) Overvalued in 2026?
Based on GuruFocus' analysis, Ascend Wellness Holdings stock appears to be undervalued.
The current stock price of $0.40 is trading 45.2% below its estimated GF Value™ of $0.73.
GuruFocus considers Ascend Wellness Holdings to be Possible Value Trap.
Key valuation signals for AAWH:
EV-to-EBIT: -40.75
GF Value™: $0.73 vs. price of $0.40 (45.2% below fair value)
No single metric tells the full story. See the AAWH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascend Wellness Holdings Inc is a vertically integrated multi-state operator focused on adult-use or near-term adult-use cannabis states in limited licenses markets. The company's core business is the cultivation, manufacturing, and distribution of cannabis consumer packaged goods, which it sells through company-owned retail stores and third-party licensed cannabis retail stores. It generates maximum revenue from the retail product segment.
46GF Score
Get the complete analysis for AAWH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AAWH has been successfully added to your 
